Chemical Inhibitors of 15-prostaglandin dehydrogenase Potentiate Hematopoietic Stem Cell Transplantation
15-前列腺素脱氢酶化学抑制剂增强造血干细胞移植
基本信息
- 批准号:9324688
- 负责人:
- 金额:$ 52.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-10 至 2020-02-28
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAlpha CellBindingBiologicalBiological AssayBiologyBloodBlood Cell CountBlood CellsBlood PlateletsBone MarrowBone Marrow PurgingBone Marrow TransplantationCSF3 geneCellsChemicalsColonComplexComputer SimulationDataDiarrheaDinoprostoneDoctor of PhilosophyDoseDrug TargetingDysmyelopoietic SyndromesElementsEngraftmentEnterocolitisEnzymesErythrocytesFluorouracilGenerationsGoalsHalf-LifeHematologic NeoplasmsHematopoieticHematopoietic Stem Cell TransplantationHematopoietic stem cellsHemorrhageHomingHospitalizationHumanIn VitroInfectionInjuryIntestinal MucosaLeadLeukocytesMalabsorption SyndromesMeasuresMelphalanModelingMorbidity - disease rateMultiple MyelomaMusOxidoreductasePatientsPharmaceutical ChemistryPharmaceutical PreparationsPharmacodynamicsPharmacotherapyPlatelet Count measurementPre-Clinical ModelPredispositionPreparationProliferatingPropertyProstaglandinsProtocols documentationPublicationsRadiationRecoveryRed Blood Cell CountRegimenReportingRodent ModelSafetyScheduleScienceSignal TransductionSolubilitySpeedTechnologyTestingTissuesTransplantation ConditioningUlcerWhite Blood Cell Count procedureWhole-Body IrradiationX-Ray Crystallographyanalogaqueousbasechemotherapycompare effectivenessconditioningcurative treatmentsdesigneffective therapygastrointestinalgut microbiotahealinghigh riskhuman morbidityimprovedin vivoinhibitor/antagonistleukemia/lymphomalipophilicitymortalityneutrophilnew therapeutic targetnoveloncologyperipheral bloodpreventreceptorreconstitutionsmall moleculesmall molecule inhibitorstandard of carethree dimensional structuretissue regenerationtooltreatment duration
项目摘要
Project Summary/Abstract
We aim to develop probe compounds to validate 15-prostaglandin dehydrogenase (15-PGDH) as a novel drug
target for accelerating recovery from hematopoietic stem cell transplantation (HST). HST, including bone
marrow transplantation (BMT) is a curative treatment for hematological malignancies including leukemias,
lymphomas, myelodysplasias, and multiple myeloma. However, recovery from HST is slow, requiring extended
hospitalization. Patients are at high risk of infections resulting from low white blood cell counts, bleeding
resulting from low platelet count, and are anemic, resulting from low red blood cell counts. Our broad objective
is to develop small molecule inhibitors of 15-PGDH to test the hypothesis that these inhibitors will elevate
tissue levels of prostaglandin E2 in vivo, and thereby accelerate recovery of white blood cells, red blood cells
and platelets following HST. Moreover, we seek to validate 15-PGDH as a novel target for the treatment
chemotherapy induced gastrointestinal enterocolitis, a severe side effect of HST conditioning. Importantly, no
current treatments exist for drug-induced enterocolitis or for accelerating recovery following HST.
In a recent article in Science, we described the first in vivo active inhibitor of 15-PGDH. This enzyme
metabolizes PGE2 to its biologically inactive form, 15-keto-PGE2. The small molecule SW033291 inhibits 15-
PGDH with Ki<1 nM. In vivo, SW033291 doubles PGE2 levels in the bone marrow and colon. Through this
effect, SW033291 accelerates hematopoietic recovery after bone marrow transplantation in mice. It speeds the
return of neutrophils, platelets and erythrocytes by 6 days. Moreover, SW033291 protected the colon and
intestinal mucosa of mice that had been treated with either DSS or the chemotherapeutic 5-FU. By speeding
bone marrow recovery and preventing enterocolitis, inhibitors of 15-PGDH have promise to markedly reduce i)
infection and bleeding complications, and ii) their associated mortality and morbidity in human hematopoietic
stem cell transplantation.
Aim 1 focuses on medicinal chemistry. SW033291 suffers from low aqueous solubility, high lipophilicity,
and functionality that could generate reactive metabolites. A second generation inhibitor substantially improves
the polarity and solubility profile, but displays a short in vivo half-life and a modest hERG signal. In Aims 2 and
3, we will confirm that our inhibitors engage 15-PGDH and will optimize treatment duration to promote recovery
of blood cells and block enterocolitis. We will also compare the effectiveness of inhibition of 15-PGDH versus
the current standard of care G-CSF, for which we have already demonstrated at least an additive effect. We
will additionally compare the effectiveness of 15-PGDH inhibition verses a competing technology. Finally, in
aim 4 we will test our optimized inhibitors in rigorous preclinical models of efficacy and safety. Broadly, our
goals are to 1) validate a new target for accelerating recovery from hematopoietic stem cell transplant, and 2)
provide safe, potent and selective inhibitors of 15-PGDH as validated drug leads.
项目总结/摘要
我们的目标是开发探针化合物,以验证15-前列腺素脱氢酶(15-PGDH)作为一种新型药物
加速造血干细胞移植(HST)恢复的靶点。HST,包括骨
骨髓移植(BMT)是血液恶性肿瘤包括白血病的治愈性治疗,
淋巴瘤、骨髓增生异常和多发性骨髓瘤。然而,从HST恢复是缓慢的,需要延长
住院由于白色血细胞计数低,出血,
由于血小板计数低而导致的贫血,以及由于红细胞计数低而导致的贫血。我们的广泛目标
是开发15-PGDH的小分子抑制剂,以测试这些抑制剂将提高
组织中的前列腺素E2在体内的水平,从而加速恢复白色血细胞,红细胞
HST后的血小板。此外,我们试图验证15-PGDH作为治疗的新靶点,
化疗引起的胃肠小肠结肠炎,HST预处理的严重副作用。重要的是没有
目前存在用于药物诱导的小肠结肠炎或用于加速HST后恢复的治疗方法。
在最近发表在《科学》杂志上的一篇文章中,我们描述了15-PGDH的第一个体内活性抑制剂。这种酶
将PGE 2代谢成其生物学上无活性的形式15-酮-PGE 2。小分子SW 033291抑制15-
PGDH,Ki<1 nM。在体内,SW 033291使骨髓和结肠中的PGE 2水平加倍。通过这个
SW 033291可加速小鼠骨髓移植后的造血恢复。它加速了
中性粒细胞、血小板和红细胞在6天内恢复。此外,SW 033291保护结肠,
用DSS或化疗剂5-FU处理的小鼠的肠粘膜。通过加快
骨髓恢复和预防小肠结肠炎,15-PGDH的抑制剂有希望显著降低i)
感染和出血并发症,和ii)其相关的死亡率和发病率在人类造血干细胞
干细胞移植
目标1侧重于药物化学。SW 033291具有低水溶性、高亲脂性,
和能够产生活性代谢物的功能。第二代抑制剂显著改善了
极性和溶解度曲线,但显示出短的体内半衰期和适度的hERG信号。在目标2和
3,我们将确认我们的抑制剂与15-PGDH结合,并将优化治疗持续时间以促进恢复
和阻止小肠结肠炎。我们还将比较抑制15-PGDH与
目前的标准治疗G-CSF,我们已经证明了至少有累加效应。我们
将另外比较15-PGDH抑制与竞争技术的有效性。最后在
目标4我们将在严格的临床前模型中测试我们优化的抑制剂的有效性和安全性。总的来说,我们
目标是1)验证加速造血干细胞移植恢复的新目标,以及2)
提供安全、有效和选择性的15-PGDH抑制剂作为经验证的先导药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STANTON L. GERSON其他文献
STANTON L. GERSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STANTON L. GERSON', 18)}}的其他基金
Molecular determinants of lung cancer in HIV infected and uninfected individuals in Uganda and Tanzania
乌干达和坦桑尼亚艾滋病毒感染者和未感染者肺癌的分子决定因素
- 批准号:
10084628 - 财政年份:2020
- 资助金额:
$ 52.07万 - 项目类别:
Molecular determinants of lung cancer in HIV infected and uninfected individuals in Uganda and Tanzania
乌干达和坦桑尼亚艾滋病毒感染者和未感染者肺癌的分子决定因素
- 批准号:
10267199 - 财政年份:2020
- 资助金额:
$ 52.07万 - 项目类别:
Molecular determinants of lung cancer in HIV infected and uninfected individuals in Uganda and Tanzania
乌干达和坦桑尼亚艾滋病毒感染者和未感染者肺癌的分子决定因素
- 批准号:
10478912 - 财政年份:2020
- 资助金额:
$ 52.07万 - 项目类别:
Lung cancer in East Africa and the relationship to HIV-1 infection: epidemiology, molecular characterization and imaging
东非肺癌及其与 HIV-1 感染的关系:流行病学、分子特征和影像学
- 批准号:
10267194 - 财政年份:2020
- 资助金额:
$ 52.07万 - 项目类别:
Lung cancer in East Africa and the relationship to HIV-1 infection: epidemiology, molecular characterization and imaging
东非肺癌及其与 HIV-1 感染的关系:流行病学、分子特征和影像学
- 批准号:
10478899 - 财政年份:2020
- 资助金额:
$ 52.07万 - 项目类别:
Lung cancer in East Africa and the relationship to HIV-1 infection: epidemiology, molecular characterization and imaging
东非肺癌及其与 HIV-1 感染的关系:流行病学、分子特征和影像学
- 批准号:
10084623 - 财政年份:2020
- 资助金额:
$ 52.07万 - 项目类别:
Chemoprotection & Immune Remodeling after Hematopoietic Progenitor Cell Gene Therapy for Glioblastoma
化学保护
- 批准号:
10470774 - 财政年份:2019
- 资助金额:
$ 52.07万 - 项目类别:
MSC 2013: Adult Stem Cell Therapy and Regenerative Medicine
MSC 2013:成体干细胞治疗和再生医学
- 批准号:
8597780 - 财政年份:2013
- 资助金额:
$ 52.07万 - 项目类别:
相似海外基金
The Role of Arginine Transport on Pancreatic Alpha Cell Proliferation and Function
精氨酸转运对胰腺α细胞增殖和功能的作用
- 批准号:
10678248 - 财政年份:2023
- 资助金额:
$ 52.07万 - 项目类别:
Alpha cell-derived Extracellular Vesicles and Maternal Insulin Production
α细胞来源的细胞外囊泡和母体胰岛素的产生
- 批准号:
10681939 - 财政年份:2023
- 资助金额:
$ 52.07万 - 项目类别:
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
- 批准号:
10427574 - 财政年份:2022
- 资助金额:
$ 52.07万 - 项目类别:
Regulation of alpha-cell glucagon secretion by mitochondrial anaplerosis-cataplerosis
线粒体回补-回补对α细胞胰高血糖素分泌的调节
- 批准号:
10607392 - 财政年份:2022
- 资助金额:
$ 52.07万 - 项目类别:
Arginine regulation of alpha cell proliferation and function
精氨酸调节α细胞增殖和功能
- 批准号:
10609909 - 财政年份:2022
- 资助金额:
$ 52.07万 - 项目类别:
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
- 批准号:
10675646 - 财政年份:2022
- 资助金额:
$ 52.07万 - 项目类别:
Elucidating alpha cell defects in human type 1 diabetes using precision cut pancreas slice-on-a-chip coupled with high spatio-temporal microscopy
使用精密切割的胰腺切片结合高时空显微镜阐明人类 1 型糖尿病的 α 细胞缺陷
- 批准号:
457552 - 财政年份:2021
- 资助金额:
$ 52.07万 - 项目类别:
Studentship Programs
Defining alpha-cell proglucagon processing for type 2 diabetes treatment
定义 2 型糖尿病治疗的 α 细胞胰高血糖素原加工过程
- 批准号:
10331361 - 财政年份:2020
- 资助金额:
$ 52.07万 - 项目类别:
In vivo systems to discover mechanisms regulating human islet alpha cell function
体内系统发现调节人类胰岛α细胞功能的机制
- 批准号:
10623306 - 财政年份:2020
- 资助金额:
$ 52.07万 - 项目类别:
Deciphering alpha-cell heterogeneity using a novel reporter mouse
使用新型报告小鼠解读α细胞异质性
- 批准号:
20K08895 - 财政年份:2020
- 资助金额:
$ 52.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)